These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16724087)

  • 1. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation.
    Liu Y
    Kidney Int; 2006 Jun; 69(11):1925-7. PubMed ID: 16724087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.
    Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
    Nephrol Dial Transplant; 2008 Sep; 23(9):2768-76. PubMed ID: 18445640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis.
    Wu MJ; Wen MC; Chiu YT; Chiou YY; Shu KH; Tang MJ
    Kidney Int; 2006 Jun; 69(11):2029-36. PubMed ID: 16732193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
    Huber TB; Walz G; Kuehn EW
    Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
    J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin: a new string to the antiproteinuric bow?
    Brunskill NJ
    J Am Soc Nephrol; 2005 Jul; 16(7):1878-9. PubMed ID: 15944334
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
    Sereno J; Parada B; Rodrigues-Santos P; Lopes PC; Carvalho E; Vala H; Teixeira-Lemos E; Alves R; Figueiredo A; Mota A; Teixeira F; Reis F
    Transplant Proc; 2013 Apr; 45(3):1149-56. PubMed ID: 23622648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin.
    Loverre A; Ditonno P; Crovace A; Gesualdo L; Ranieri E; Pontrelli P; Stallone G; Infante B; Schena A; Di Paolo S; Capobianco C; Ursi M; Palazzo S; Battaglia M; Selvaggi FP; Schena FP; Grandaliano G
    J Am Soc Nephrol; 2004 Oct; 15(10):2675-86. PubMed ID: 15466272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rapamycin: a new immunosuppressive agent capable of inhibiting chronic rejection?].
    Viklický O; Matl I
    Cas Lek Cesk; 2001 Jan; 140(1):22-5. PubMed ID: 11242980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of delayed rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury.
    Liu M; Agreda P; Crow M; Racusen L; Rabb H
    Transplant Proc; 2009 Dec; 41(10):4065-71. PubMed ID: 20005342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
    Pontrelli P; Rossini M; Infante B; Stallone G; Schena A; Loverre A; Ursi M; Verrienti R; Maiorano A; Zaza G; Ranieri E; Gesualdo L; Ditonno P; Bettocchi C; Schena FP; Grandaliano G
    Transplantation; 2008 Jan; 85(1):125-34. PubMed ID: 18192922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation.
    Geissler EK; Schlitt HJ
    Kidney Int; 2010 Dec; 78(11):1075-9. PubMed ID: 20861822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.